Atrial Cardiomyopathy and Ischemic Stroke: A Monitoring-Integrated Staging and Phenotyping Framework Beyond Atrial Fibrillation
- 1Department of Cardiology, Renmin Hospital, Hubei University of Medicine, 442000 Shiyan, Hubei, China
- 2Department of Pulmonary and Critical Care Medicine, Renmin Hospital, Hubei University of Medicine, 442000 Shiyan, Hubei, China
Abstract
In many patients with cryptogenic stroke or embolic stroke of undetermined source (ESUS), the atrium remains clinically relevant even when atrial fibrillation (AF) is not detected with routine or extended cardiac monitoring. The construct of atrial cardiomyopathy (AtCM) addresses this problem by characterizing a measurable atrial substrate rather than relying solely on a binary search for AF. Thus, this narrative review proposes a framework that integrates cardiac monitoring with a staging system to describe AtCM following ischemic stroke. Moreover, this review distinguishes arrhythmogenic AtCM, which primarily facilitates AF detection, from thrombogenic AtCM, an emerging concept that reflects blood stasis, left atrial appendage dysfunction, endocardial–endothelial activation, and coagulation activation. Recent neutral or mixed anticoagulation trials suggest that broad atrial stress markers are insufficient for selecting patients for empiric anticoagulation. Therefore, we present a Stage 0–4 classification system that links phenotype burden to monitoring intensity and research eligibility. This framework is intended to standardize reporting, guide the intensity of monitoring, support upstream risk-factor management, and improve trial enrichment. However, this framework is not intended to replace guideline-based decisions regarding antithrombotic therapy.
Related
- Atrial fibroblast metabolic reprogramming in atrial fibrillation: a candidate mechanism within multicellular atrial cardiomyopathy
- Recurrence Rates and Outcomes After First Detected Atrial Fibrillation Episode in a Contemporary Hypertrophic Cardiomyopathy Center
- Phenotyping of Arrhythmia-induced Cardiomyopathy: From Bench to Bedside and Back
- Case Report: Suspected biventricular arrhythmogenic cardiomyopathy presenting as a dilated cardiomyopathy-like phenotype with multimodal phenotyping and cautious genetic interpretation
- Life-long management of atrial fibrillation in a patient with hypertrophic obstructive cardiomyopathy following alcohol septal ablation: A10-year follow-up case report
BibTeX
@article{cao2026atrial,
title = {{Atrial Cardiomyopathy and Ischemic Stroke: A Monitoring-Integrated Staging and Phenotyping Framework Beyond Atrial Fibrillation}},
author = {Ye Cao and Qunxiong Fan and Qing Hao and Yi Feng},
journal = {Reviews in Cardiovascular Medicine},
year = {2026},
month = oct,
doi = {10.31083/rcm51244},
url = {https://doi.org/10.31083/rcm51244},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Atrial Cardiomyopathy and Ischemic Stroke: A Monitoring-Integrated Staging and Phenotyping Framework Beyond Atrial Fibrillation
AU - Ye Cao
AU - Qunxiong Fan
AU - Qing Hao
AU - Yi Feng
PY - 2026
DA - 2026/10/13
JO - Reviews in Cardiovascular Medicine
DO - 10.31083/rcm51244
UR - https://doi.org/10.31083/rcm51244
AB - In many patients with cryptogenic stroke or embolic stroke of undetermined source (ESUS), the atrium remains clinically relevant even when atrial fibrillation (AF) is not detected with routine or extended cardiac monitoring. The construct of atrial cardiomyopathy (AtCM) addresses this problem by characterizing a measurable atrial substrate rather than relying solely on a binary search for AF. Thus, this narrative review proposes a framework that integrates cardiac monitoring with a staging system to describe AtCM following ischemic stroke. Moreover, this review distinguishes arrhythmogenic AtCM, which primarily facilitates AF detection, from thrombogenic AtCM, an emerging concept that reflects blood stasis, left atrial appendage dysfunction, endocardial–endothelial activation, and coagulation activation. Recent neutral or mixed anticoagulation trials suggest that broad atrial stress markers are insufficient for selecting patients for empiric anticoagulation. Therefore, we present a Stage 0–4 classification system that links phenotype burden to monitoring intensity and research eligibility. This framework is intended to standardize reporting, guide the intensity of monitoring, support upstream risk-factor management, and improve trial enrichment. However, this framework is not intended to replace guideline-based decisions regarding antithrombotic therapy.
SN - 1530-6550
SN - 2153-8174
ER -